Targeted Therapies On FDA’s Orphan Designation Radar

As personalized medicine continues to grow, FDA is watching to see if there is a rise in orphan designations for products targeting a “smaller slice” of a common disease.

FDA is on the lookout for the effects of personalized medicine on the orphan drug program and the potential for all diseases to be defined in such a way that they become eligible for orphan status.

As the therapeutic principles behind personalized medicine continue to develop, there may be more drugs targeted at smaller, more specific...

More from United States

More from North America